ClinicalTrials.gg

Program

Rifaximin

Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.

Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.

Furthest: phase 4, since Apr 16, 201322 company-led studies, 1 open or runningNext primary completion: Apr 20, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies161 open or runningphase 4since Apr 16, 2013Dec 22, 2005Apr 20, 2027phase 4 · NCT07285785
Alfasigma40 open or runningphase 2since Feb 19, 2015Feb 19, 2015none ahead
Novartis10 open or runningphase 3since Sep 29, 2016Sep 29, 2016none ahead
Teva Pharmaceutical Industries10 open or runningphase 3since Jul 9, 2015Jul 9, 2015none ahead

Also a collaborator on its studies: biorasi-llc, cromsource and parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 7 studies since Dec 22, 2005.

  1. Aug 24, 2008Phase 3 study in DiarrheaBausch Health Companies · NCT00742469 · 210 enrolled · Mexico
  2. Aug 27, 2008Phase 1 study in PharmacokineticBausch Health Companies · NCT00743912 · 24 enrolled
  3. Feb 27, 2012Phase 3 study in DiarrheaBausch Health Companies · NCT01543178 · 2,583 enrolled · United States, Germany, United Kingdom
  4. Apr 16, 20132 phase 4 studies in Hepatic EncephalopathyBausch Health Companies · NCT01842581, NCT01846663
  5. Jul 17, 2013Phase 2 study in Liver CirrhosisBausch Health Companies · NCT01904409 · 420 enrolled · United States, Russian Federation
  6. Feb 19, 2015Alfasigma's first study: phase 2 study in Vaginosis, BacterialNew to AlfasigmaAlfasigma · NCT02376972 · 392 enrolled · United States
  7. Jul 9, 2015Teva Pharmaceutical Industries's first study: phase 3 study in DiarrheaNew to Teva Pharmaceutical IndustriesTeva Pharmaceutical Industries · NCT02498418 · 739 enrolled · United States
  8. Sep 29, 2016Novartis's first study: phase 3 study in DiarrheaNew to NovartisNovartis · NCT02920242 · 28 enrolled · Mexico
  9. May 15, 2018Phase 2 study in Crohn DiseaseAlfasigma · NCT03537157 · 43 enrolled · Italy
  10. Jan 22, 2019Phase 4 study in Severe Hepatic ImpairmentBausch Health Companies · NCT03818672 · 5 enrolled · United States
  11. Mar 5, 2019Phase 2 study in RosaceaAlfasigma · NCT03864978 · 236 enrolled · Italy
  12. Oct 18, 2021Phase 2 study in Anemia, Sickle CellBausch Health Companies · NCT05098028 · 44 enrolled · United States, Canada, Kenya
  13. Oct 25, 2021Phase 2 study in RosaceaAlfasigma · NCT05150587 · 216 enrolled · United States
  14. Dec 2, 2025Phase 4 study in DiarrheaBausch Health Companies · NCT07285785 · 54 planned · United States

Ahead

  1. Apr 20, 2027Primary completion: phase 4 study in DiarrheaBausch Health Companies · NCT07285785

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 22 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07285785Diarrhea · United States4RecruitingBausch Health CompaniesApr 20, 202754
NCT05150587Rosacea · United States2CompletedAlfasigmaOct 20, 2022216
NCT05098028Anemia, Sickle Cell · United States, Canada, Kenya2CompletedBausch Health CompaniesSep 4, 202344
NCT03864978Rosacea · Italy2UNKNOWNAlfasigmaApr 2020236
NCT03818672Severe Hepatic Impairment · United States4TerminatedBausch Health CompaniesFeb 2, 20205
NCT03537157Crohn Disease · Italy2TerminatedAlfasigmaJul 15, 202043
NCT02920242Diarrhea · Mexico3TerminatedNovartisMay 23, 201728
NCT02498418Diarrhea · United States3CompletedTeva Pharmaceutical IndustriesFeb 28, 2017739
NCT02376972Vaginosis, Bacterial · United States2TerminatedAlfasigmaFeb 2016392
NCT01904409Liver Cirrhosis · United States, Russian Federation2CompletedBausch Health CompaniesJun 2015420
NCT01846663Hepatic Encephalopathy · United States4TerminatedBausch Health CompaniesFeb 22, 20166
NCT01842581Hepatic Encephalopathy · United States4CompletedBausch Health CompaniesDec 17, 2014222
NCT01543178Diarrhea · United States, Germany, United Kingdom3CompletedBausch Health CompaniesJun 20142,583
NCT00743912Pharmacokinetic1CompletedBausch Health CompaniesOct 200824
NCT00742469Diarrhea · Mexico3CompletedBausch Health CompaniesSep 2005210
NCT00724126Diarrhea · United States3CompletedBausch Health CompaniesAug 2009637
NCT00731679Abdominal Pain · United States, Canada3CompletedBausch Health CompaniesAug 2009623
NCT00686920Hepatic Encephalopathy · United States, Canada3CompletedBausch Health CompaniesDec 8, 2010322
NCT00328380Diarrhea · United States3CompletedBausch Health CompaniesDec 2006660
NCT00298038Hepatic Encephalopathy3CompletedBausch Health CompaniesAug 15, 2008299
NCT00269412Irritable Bowel Syndrome · United States2CompletedBausch Health CompaniesAug 2007525
NCT00269399Clostridium Infections · United States3CompletedBausch Health CompaniesDec 2008237

How it is read

Names in the registry

  • “Rifaximin”, 12 entries
  • “Rifaximin 200 mg Tablet”, 1 entry
  • “Low Dose Rifaximin ER”, 1 entry
  • “High Dose Rifaximin ER”, 1 entry
  • “Rifaximin delayed release tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.